Nursing Care for Patients Receiving Cellular & BsAb Therapies | Belal Alblowe | SSBMT 2026

Building a Safe and High-Performing BMT Program | Mohamed Basheer | SSBMT 2026

CAR-T Cell Therapy: Patient Journey | Belal AlBtoosh | SSBMT 2026

Outpatient Transplant for Lymphoma Patients | Hamza Al-Quraan | SSBMT 2026

Enhancing Transplantation Rates for Sickle Cell Disease | Maram Haddad | SSBMT 2026

Transforming Hematology Care: Acute Leukemia & Multiple Myeloma | S. Alkhraisat | SSBMT 2026

The Impact of Novel Therapeutics on Clinical Nurse Education | Silvia Gnecchi | SSBMT 2026

Malignant Hematology & Recent Update in HL (Hodgkin Lymphoma) | Izaskun Zeberio | SSBMT 2026

Best of the Best of EBMT 2026 | Hilda Mekelenkamp | SSBMT 2026

Hemoglobinopathies | Prof. Selim Corbacioglu | SSBMT 2026

TA-TMA Diagnostic Criteria | Dr. Eleni Gavriilaki | SSBMT 2026

HLH & IEC-HS: Hemophagocytic Lymphohistiocytosis | Hind Salama | SSBMT 2026

Gene Editing Therapy Updates for SCD and TDT | Dr. Fahad Al Manjomii | SSBMT 2026

Myelofibrosis Management: Addressing Patients' Unmet Needs | Dr. Albanyan | SSBMT 2026

Paroxysmal Nocturnal Hemoglobinuria (PNH) | Dr. Ashraf Warsi | SSBMT 2026

Integrating Novel Agents & Allo-HCT in Myelofibrosis | Dr. Hernández Boluda | SSBMT 2026

Guidelines & Key Determinants for Treatment Choice in SAA | Prof. Risitano | SSBMT 2026

FromEvidence to Action:Real-World Management of Myelofibrosis Patients-Dr. Ayman Almozaini-SSBMT2026

Advances in MPN: Updates in Myelofibrosis Management | Dr. Rawan Almohamady | SSBMT 2026

What Are the Current Common Approaches to Treat CML? | Dr. Ayel Yahya | SSBMT 2026

AML: Focus on Menin Inhibitors | Dr. Bader Alahmari | 15th Annual Conference SSBMT 2026

Advancing cGVHD Care: From Evidence to Practice | Dr. Bader Alahmari | SSBMT 2026

Transplantation and Gene Therapy in Thalassemia and Sickle Cell Disease | 15th Annual Conf SSBMT2026

The Use of Expanded Cord in Patients with High-Risk Malignancies | Prof. Guy Sauvageau | SSBMT 2026

Armored and In Vivo Next-Gen CARs | Prof. He Huang | 15th Annual SSBMTConference/EBMT 2026Highlights

2026 Updates in Relapsed/Refractory CLL | Dr. Musa Alzahrani | 15th Annual Conference SSBMT 2026

Optimizing Treatment Strategies in Multiple Myeloma—A Focus on BCMA |15th Annual ConferenceSSBMT2026

SupportiveCare in IntestinalGVHD-Nutrition &Supplementation-Dr. Zinaida Perić-15thAnnualConSSBMT2026

Navigating Treatment Options After Covalent BTKi Failure-Dr. Omar Albanyan-15th Annual Con SSBMT2026

Ph-Negative B-cell ALLin Pediatrics Frontline & Salvage Strategies | 15thAnnual Conference SSBMT2026

Sequencing of Bispecifics and CAR-T in Myeloma — 15th Annual SSBMT Conference / EBMT 2026 Highlights

Rejuvenating the Cord Blood Transplantation — 15th Annual SSBMT Conference / EBMT 2026 Highlights

Lymphoma mimickers & Diagnostic Traps | Alfadel Alshaibani | 31 JAN 2026

Overview on Platelets Products in Clinical Practice | Salwa Hindawi | 31 JAN 2026

Cancer Associated Thrombosis (CAT) | Sarah Sewaralthahab | 31 JAN 2026

Complicated cases of thrombosis – challenges in management | Ashraf Warsi | 31 JAN 2026

Richter’s Transformation | Mohammed Almakadi | 31 JAN 2026

Hodgkin Lymphoma–therapy sequencing in the era of upfront biologic therapy |Ahmed Barefah |31JAN2026

Fixed duration Novel agents’ combinations in CLL upfront therapy | Ahmed Absi | 31 JAN 2026

Neutrophilia other than CML | Hanan Hamed | 31 JAN 2026

Eosinophilic Updates to Old Approaches | Osman Radhwi | 30 JAN 2026

GVHD 2025: New Predictive Biomarkers and Treatment Algorithms | Naif Aljohani | 30 JAN 2026

MPNs: JAK Inhibitors vs New Pathway Inhibitors— When to Switch Therapy | Sultan Altouri |30 JAN 2026

CML 2025:Achieving Treatment-Free Remission—Patient Selection Algorithm | Ihab Elhemaidi |30JAN 2026

Challenges in Thalassemia for Precision Medicine: Evidence Based Research| Soad Aljaouni|30 JAN 2026

Emerging Therapies in β-Thalassemia — Luspatercept and Beyond | Abdullah Alzayed | 30 JAN 2026

Managing Challenging Cases: Sickle Cell disease | Gad Allah Ali | 30 JAN 2026

Gene Therapy for SCD and TDT — Clinical and Economic Reality | Mohsen Alzahrani | 30 JAN 2026

Gene Therapies: A New Era in Hemoglobinopathies | Ihab Elehmaidi | 30 JAN 2026

Emerging role of BCMA targeting in management of RRMM | Ghazi Alotaibi | 30 JAN 2026

Plasma Cell Leukemia – Update on therapy SOC | Majed Alahmadi | 30 JAN 2026

MRD Negativity in Multiple Myeloma: A New Treatment Endpoint| Ghazi Alotaibi | 30 JAN 2026

CAR-T vs Bispecific Antibodies in Myeloma—Bridging Strategies& supportive measures|Abdullah Alsaleh

ALL:How does the future look like w/ Incorporation of upfront Novel therapies | Saleem Eldadah

Frontline Management in Multiple Myeloma | Ayman Alhejazi | 30 JAN 2026

HIV Associated Lymphomas | Hafiz Malhan | 30 JAN 2026

Is there still a role for ASCT in Mantle Cell Lymphoma | Reyad Dada | 30 JAN 2026

Now Is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma | Mubarak Almansour| 30JAN 2026

CAR-T vs Bispecific Antibodies in Aggressive Lymphoma | Sameer Alamoudi | 30 JAN 2026

Philadelphia positive ALL -Best First Line Therapy | Nahla Shihata | 30 JAN 2026